Neurodon Welcomes Brunde Broady to its Board of Directors
Neurodon Corporation announced today the appointment of a new member to the company’s board of directors, effective immediately. Joining the board is experienced business leader Brunde Broady.
“We are excited to welcome Brunde to our board of directors. She brings decades of leadership experience in key areas critical to the growth of our business and vital to our future operations and strategy,” said Dr. Russell Dahl, Neurodon’s CEO, and founder. “Brunde’s expertise is especially valuable to Neurodon as an emerging company. In addition, her knowledge and interest in our therapeutic strategy and biological targets creates a synergy that will contribute to our success.”
Brunde graduated from Yale’s MBA program and became a partner in a family-controlled venture firm. The firm maintains several long-term investments and has funded several start-ups from their inception. The firm’s worldwide portfolio has interests in England, Germany, and China in nutraceuticals, software, technology, and, most recently, biopharma. Her network of individuals and companies has long standing relationships with individuals at the NIH, FDA, academic Institutions, as well as pharma and biotech VCs.
Neurodon is a development-stage pharmaceutical company dedicated to finding disease-modifying drugs for diabetes, neurodegeneration, and other life-threatening diseases. Neurodon deploys its proprietary ER stress-based technology platform to discover compounds that can reduce the cellular dysfunction that is the root cause of these diseases. The company’s pipeline includes therapies for diabetes and neurodegeneration that are slated to enter IND-enabling studies in the coming months.